The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Hepatitis B Treatment Oral Drugs Market Research Report 2024
Synopsis
The global Chronic Hepatitis B Treatment Oral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chronic Hepatitis B Treatment Oral Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chronic Hepatitis B Treatment Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Hepatitis B Treatment Oral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Hepatitis B Treatment Oral Drugs.
The Chronic Hepatitis B Treatment Oral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Hepatitis B Treatment Oral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Hepatitis B Treatment Oral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Hepatitis B Treatment Oral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Chronic Hepatitis B Treatment Oral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Hepatitis B Treatment Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Chronic Hepatitis B Treatment Oral Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Chronic Hepatitis B Treatment Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Hepatitis B Treatment Oral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Hepatitis B Treatment Oral Drugs.
The Chronic Hepatitis B Treatment Oral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Hepatitis B Treatment Oral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Hepatitis B Treatment Oral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Hepatitis B Treatment Oral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Perspective (2019-2030)
2.2 Global Chronic Hepatitis B Treatment Oral Drugs Growth Trends by Region
2.2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Region (2019-2024)
2.2.3 Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Region (2025-2030)
2.3 Chronic Hepatitis B Treatment Oral Drugs Market Dynamics
2.3.1 Chronic Hepatitis B Treatment Oral Drugs Industry Trends
2.3.2 Chronic Hepatitis B Treatment Oral Drugs Market Drivers
2.3.3 Chronic Hepatitis B Treatment Oral Drugs Market Challenges
2.3.4 Chronic Hepatitis B Treatment Oral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue
3.1.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue (2019-2024)
3.1.2 Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Hepatitis B Treatment Oral Drugs Revenue
3.4 Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration Ratio
3.4.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Hepatitis B Treatment Oral Drugs Revenue in 2023
3.5 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs Head office and Area Served
3.6 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Product and Application
3.7 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Type
4.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Type (2019-2024)
4.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Type (2025-2030)
5 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Application
5.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Application (2019-2024)
5.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Hepatitis B Treatment Oral Drugs Market Size (2019-2030)
6.2 North America Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024)
6.4 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size (2019-2030)
7.2 Europe Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024)
7.4 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size (2019-2030)
8.2 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size (2019-2030)
9.2 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024)
9.4 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size (2019-2030)
10.2 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Treatment Oral Drugs Introduction
11.1.4 GSK Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Introduction
11.3.4 Gilead Sciences Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Treatment Oral Drugs Introduction
11.4.4 Novartis Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Treatment Oral Drugs Introduction
11.5.4 Roche Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Treatment Oral Drugs Introduction
11.6.4 Merck Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Company Details
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.8.4 Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.8.5 Dawnrays Pharmaceutical Recent Development
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Company Details
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.9.4 Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.9.5 Hansoh Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Company Details
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Company Details
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.11.4 Qilu pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.11.5 Qilu pharmaceutical Recent Development
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Company Details
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Introduction
11.12.4 Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.12.5 Fujian Cosunter Pharma Recent Development
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Company Details
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Introduction
11.13.4 Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.13.5 Xiamen Amoytop Biotech Recent Development
11.14 YaoPharma
11.14.1 YaoPharma Company Details
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Treatment Oral Drugs Introduction
11.14.4 YaoPharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.14.5 YaoPharma Recent Development
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Company Details
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction
11.15.4 Kelun Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
11.15.5 Kelun Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Entecavir
Table 3. Key Players of Tenofovir
Table 4. Key Players of Lamivudine
Table 5. Key Players of Adefovir
Table 6. Key Players of Telbivudine
Table 7. Key Players of Others
Table 8. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2019-2024)
Table 12. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2025-2030)
Table 14. Chronic Hepatitis B Treatment Oral Drugs Market Trends
Table 15. Chronic Hepatitis B Treatment Oral Drugs Market Drivers
Table 16. Chronic Hepatitis B Treatment Oral Drugs Market Challenges
Table 17. Chronic Hepatitis B Treatment Oral Drugs Market Restraints
Table 18. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Players (2019-2024)
Table 20. Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Treatment Oral Drugs as of 2023)
Table 21. Ranking of Global Top Chronic Hepatitis B Treatment Oral Drugs Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Chronic Hepatitis B Treatment Oral Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 23. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Headquarters and Area Served
Table 24. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Product and Application
Table 25. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Type (2019-2024)
Table 29. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Type (2025-2030)
Table 31. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Application (2019-2024)
Table 33. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Application (2025-2030)
Table 35. North America Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. GSK Company Details
Table 51. GSK Business Overview
Table 52. GSK Chronic Hepatitis B Treatment Oral Drugs Product
Table 53. GSK Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 54. GSK Recent Development
Table 55. Bristol Myers Squibb Company Details
Table 56. Bristol Myers Squibb Business Overview
Table 57. Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Product
Table 58. Bristol Myers Squibb Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 59. Bristol Myers Squibb Recent Development
Table 60. Gilead Sciences Company Details
Table 61. Gilead Sciences Business Overview
Table 62. Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Product
Table 63. Gilead Sciences Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 64. Gilead Sciences Recent Development
Table 65. Novartis Company Details
Table 66. Novartis Business Overview
Table 67. Novartis Chronic Hepatitis B Treatment Oral Drugs Product
Table 68. Novartis Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 69. Novartis Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Chronic Hepatitis B Treatment Oral Drugs Product
Table 73. Roche Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Merck Company Details
Table 76. Merck Business Overview
Table 77. Merck Chronic Hepatitis B Treatment Oral Drugs Product
Table 78. Merck Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 79. Merck Recent Development
Table 80. Johnson & Johnson Company Details
Table 81. Johnson & Johnson Business Overview
Table 82. Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Product
Table 83. Johnson & Johnson Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 84. Johnson & Johnson Recent Development
Table 85. Dawnrays Pharmaceutical Company Details
Table 86. Dawnrays Pharmaceutical Business Overview
Table 87. Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product
Table 88. Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 89. Dawnrays Pharmaceutical Recent Development
Table 90. Hansoh Pharmaceutical Company Details
Table 91. Hansoh Pharmaceutical Business Overview
Table 92. Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product
Table 93. Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 94. Hansoh Pharmaceutical Recent Development
Table 95. Chia Tai-Tianqing Pharmaceutical Company Details
Table 96. Chia Tai-Tianqing Pharmaceutical Business Overview
Table 97. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product
Table 98. Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 99. Chia Tai-Tianqing Pharmaceutical Recent Development
Table 100. Qilu pharmaceutical Company Details
Table 101. Qilu pharmaceutical Business Overview
Table 102. Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product
Table 103. Qilu pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 104. Qilu pharmaceutical Recent Development
Table 105. Fujian Cosunter Pharma Company Details
Table 106. Fujian Cosunter Pharma Business Overview
Table 107. Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Product
Table 108. Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 109. Fujian Cosunter Pharma Recent Development
Table 110. Xiamen Amoytop Biotech Company Details
Table 111. Xiamen Amoytop Biotech Business Overview
Table 112. Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Product
Table 113. Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 114. Xiamen Amoytop Biotech Recent Development
Table 115. YaoPharma Company Details
Table 116. YaoPharma Business Overview
Table 117. YaoPharma Chronic Hepatitis B Treatment Oral Drugs Product
Table 118. YaoPharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 119. YaoPharma Recent Development
Table 120. Kelun Pharmaceutical Company Details
Table 121. Kelun Pharmaceutical Business Overview
Table 122. Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product
Table 123. Kelun Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024) & (US$ Million)
Table 124. Kelun Pharmaceutical Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Chronic Hepatitis B Treatment Oral Drugs Picture
Figure 2. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Type: 2023 VS 2030
Figure 4. Entecavir Features
Figure 5. Tenofovir Features
Figure 6. Lamivudine Features
Figure 7. Adefovir Features
Figure 8. Telbivudine Features
Figure 9. Others Features
Figure 10. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 11. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Application: 2023 VS 2030
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Chronic Hepatitis B Treatment Oral Drugs Report Years Considered
Figure 16. Global Chronic Hepatitis B Treatment Oral Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Chronic Hepatitis B Treatment Oral Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region: 2023 VS 2030
Figure 19. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Players in 2023
Figure 20. Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Treatment Oral Drugs as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Chronic Hepatitis B Treatment Oral Drugs Revenue in 2023
Figure 22. North America Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2019-2030)
Figure 24. United States Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2019-2030)
Figure 28. Germany Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2019-2030)
Figure 36. China Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2019-2030)
Figure 44. Mexico Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2019-2030)
Figure 48. Turkey Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. UAE Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. GSK Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 52. Bristol Myers Squibb Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 53. Gilead Sciences Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 54. Novartis Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 55. Roche Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 56. Merck Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 57. Johnson & Johnson Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 58. Dawnrays Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 59. Hansoh Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 60. Chia Tai-Tianqing Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 61. Qilu pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 62. Fujian Cosunter Pharma Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 63. Xiamen Amoytop Biotech Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 64. YaoPharma Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 65. Kelun Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
